$CYCU News: Cycurion Stock (Nasdaq: CYCU) Receives Buy

New Post Public Reply Private Reply Replies (0) Message Board
trooperstocks
63
$CYCU News: Cycurion Stock (Nasdaq: CYCU) Receives Buy Rating and $7 Target Price in New Investment Report Issued from Litchfield Hills Research
Cycurion
Tue, February 3, 2026 at 8:45 AM EST

Report Highlights Cycurion’s $80 Million Backlog Positioning the Company for Strong 2026 Revenue Growth

MCLEAN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leading provider of AI-driven cybersecurity, IT security solutions, and managed services is pleased to announce that Litchfield Hills Research has initiated coverage on CYCU with a Buy rating and a $7.00 price target. The target represents significant upside potential from the current CYCU stock price level with InvestingPro data showing the micro-cap company (market capitalization of just $10.68 million) is trading below its Fair Value.

Litchfield Hills Research highlighted Cycurion’s $80 million contracted backlog, approximately four times its fiscal year 2024 revenue, which positions the company for significant revenue growth as contracts convert to billable work. This backlog is particularly noteworthy given the company’s current annual revenue of $15.67 million.

Litchfield Hills also noted that Cycurion is pivoting toward higher-margin cybersecurity solutions, providing advisory services, managed services, and SaaS solutions primarily to state and local governments and small businesses—markets that remain under-secured and increasingly targeted by ransomware attacks.

The report pointed to Cycurion’s proven acquisition and integration model, built through multiple acquisitions and now operating as a unified platform under new leadership focused on simplifying structure, improving margins, and scaling higher-value managed security offerings. Investors should note that InvestingPro data shows the stock generally trades with high price volatility, with shares down 78.2% over the past six months.

Even at the $7.00 price target, Litchfield Hills indicated Cycurion would trade at 2.9x estimated 2026 revenue versus a peer average of 9.0x, reflecting what the firm called "a steep and unwarranted discount." This valuation perspective aligns with the company’s current Price/Book ratio of just 0.53, suggesting potential value for investors willing to accept the risks.

Investors may review the Litchfield Hills Research profile of Cycurion (CYCU) issued on January 23, 2026 at this direct link: https://www.investing.com/news/analyst-rating...CH-4463280.

Cycurion engaged Litchfield Hills Research to provide an independent third-party evaluation and valuation of CYCU stock, selecting the firm for its well-established reputation for objective, fact-based, and comprehensive investment analysis.

Kevin Kelly, Chairman and Chief Executive Officer of Cycurion, Inc. commented, “It is very gratifying to see the appreciation of Cycurion’s significant undervaluation at current trading prices clearly presented in the new Litchfield Hills Research profile and price target just issued. With all of the accomplishments that Cycurion has delivered to date, including our first shareholder dividend, the $80 million contracted backlog being turned into growing billable revenues and the swelling global demand for advanced cybersecurity solutions today, we are confident that long term investors who build positions in CYCU stock should be substantially rewarded, going forward. We urge everyone to review the Litchfield Hills Research coverage of Cycurion as well as all of our company’s own news announcements and filings to fully appreciate the high value investment opportunity here.”

About Cycurion, Inc.

Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies LLC, Cloudburst Security LLC, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients committed to securing the digital future. More info: www.cycurion.com

Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion’s business.

Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Such statements include, but are not limited to, statements regarding the anticipated closing of the offering; the Company’s anticipated use of proceeds from the offering; the acceleration of the Company’s inorganic growth strategy; the continued execution on the Company’s backlog; and other statements that are not historical facts, including statements which may be accompanied by words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Cycurion and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to, the outcomes of the Company’s investigations, any potential legal proceedings, or the future performance of the Company’s stock. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K filed by Cycurion with the U.S. Securities and Exchange Commission. Cycurion anticipates that subsequent events and developments may cause its plans, intentions, and expectations to change. Cycurion assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Cycurion’s plans and expectations as of any subsequent date.

Third-Party Research Disclosure

This press release includes references to, or excerpts from, an investment research report prepared by a third party, Litchfield Hills Research (the “Report”). Cycurion engaged Litchfield Hills Research to prepare the Report and paid a fee for its preparation; however, Litchfield Hills Research retained full editorial control and independence with respect to the content, opinions, estimates, projections, and price targets expressed in the Report. The views, opinions, and conclusions contained in the Report are solely those of the author as of the date of the Report and do not represent the views, opinions, or forecasts of the Company.

The Company has not independently verified, and does not accept responsibility for, the accuracy, completeness, or reliability of the information contained in the Report and has no obligation to update, revise, or comment on the Report or any opinions, estimates, or price targets contained therein. The inclusion of the Report or references thereto in this press release is not intended to, and does not, constitute an offer to sell or the solicitation of an offer to buy any securities of the Company.

The Report is not investment advice and should not be relied upon as such. Any investment decision with respect to the Company’s securities should be made based on an investor’s own independent evaluation, including consultation with professional financial, legal, and tax advisers. Past performance is not indicative of future results, and any price targets or forward-looking statements contained in the Report involve risks and uncertainties that could cause actual results to differ materially.

Cycurion Investor Relations:
(888) 341-6680
investors@cycurion.com

Cycurion Media Relations:
(888) 341-6680
media@cycurion.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ON1 Photo RAW 2027: New AI Tools, Better Processing

Updated Category News Views 50

Aiming for the Photography Crown ON1 isn't just tinkering on the fringes with their new Photo RAW 2027 release—they're diving headfirst into the deep end, aiming to outdo giants in the RAW processing world. I've seen my share of software updates that don't move the needle, but this one's packed to the gills with updates that photographers have been clamoring for. What's...

Continue Reading
China's Innovation Surge: Game Changer for Global Markets

Updated Category News Views 235

The Bold Shift in China's Economic Landscape Well, here's the scoop: China isn't just the world's assembly line anymore; it's gearing up to be a top-tier innovation hub. On the surface, might seem like another geopolitical spiel, but dig a little and you'll find it's a serious shake-up for global markets. We're talking about more than just products rolling out of...

Continue Reading
Jeep Wrangler Scrambler SRT: A Bold Off-Road Rebirth

Updated Category News Views 0

A New Legend in the Making Who would've thought we'd see the day when an SRT badge graced a Jeep Wrangler with such audacity? This ain't your typical Wrangler—they’ve slapped a bit of that CJ-8 throwback swagger, and given it the full-on SRT treatment. It's a mad machine, barreling into the future with one foot firmly planted in its legendary past. You ask any...

Continue Reading
Florida Homebuyers: Navigating Flood Zone Risks Smartly

Updated Category News Views 92

Florida Properties: The Buried Risk in Flood Zones If you’re dreaming of palm trees and sandy beaches, don't let flood zones turn that dream into a nightmare. It’s not all sunshine and rainbows when it comes to buying real estate in Florida, as it turns out—flood zones are lurking, and the devil's in the details. Understanding FEMA Flood Maps First off, these FEMA...

Continue Reading
ACA 2027 Enrollment: New Rules Aim to Simplify Coverage

Updated Category News Views 61

Navigating New Waters in 2027 ACA Open Enrollment If you're one of those folks who likes to wait until the last minute, the ACA's got a wake-up call for you this year. The 2027 open enrollment period started on November 1, 2026, with some pretty notable changes. The deadline for coverage beginning January 1, 2027, is December 15, so don't take a nap on this one, alright?...

Continue Reading
Beyon Expands Green Data Centres to Three Facilities

Updated Category News Views 37

Blazing Solar Trails in the Digital Landscape Lend an ear, folks, because Beyon's latest leap in the world of renewable energy isn't just another 'look how green we are' maneuver. Announced during Gateway Gulf 2026, this venture is all about serious numbers and even more serious energy chops. Beyon's on course to power a third data center entirely through solar energy,...

Continue Reading
Lazard Closes Deal with Campbell, Launches Lazard CL

Updated Category News Views 59

Talk about pulling a rabbit out of the hat! Lazard has just solidified its position in the private capital advisory game with the closure of its acquisition of Campbell Lutyens. They’re now rolling out Lazard CL, merging muscle across different strategies and diversifying those good ol’ revenue streams. It’s a peppy move from Lazard—not just for the cold hard...

Continue Reading
Xylitol: A Game Changer in Kids' Oral Care Battle

Updated Category News Views 91

Candy Challenges: Embracing Sweet Joys Responsibly Think you're done with Halloween? Nope. Welcome to the endless candy seasons when every festivity seems like an outlet for sugar overload—with parents caught between letting kids enjoy and guarding their teeth. Now, with Spry's recent push around xylitol, there's an option that might just mean an easier peace between...

Continue Reading
Military Medical Minds to Converge at MTEC Event in 2027

Updated Category News Views 72

Ever wonder where the cutting edge of military medicine takes shape? On February 16-17, 2027, Washington, DC becomes the epicenter for just that, as the Medical Technology Enterprise Consortium (MTEC) rolls out its 11th Annual Membership Meeting. A gathering of who's who in the world of military medical innovation, this event is like a high-stakes cocktail of science,...

Continue Reading
Sirolimus-Coated Balloon Shows Promise in TRANSFORM II

Updated Category News Views 96

Breaking Down the TRANSFORM II Trial Innovation never rests, folks, especially when it comes to treating coronary artery disease. Right on cue, the TRANSFORM II trial's results have hit the airwaves, marking a significant milestone with its implant-free MagicTouch Sirolimus-Coated Balloon (SCB) strategy. Getting the Lay of the Land This wasn't just some backyard...

Continue Reading

Top 5 Most Recently Viewed Articles

ATYR Stock Investors: Important Class Action Update

Updated Category News Views 139

Key Information for ATYR Pharma Shareholders ATYR Pharma, Inc. has recently faced significant challenges that have caught the attention of its shareholders. Investors who have purchased shares of ATYR during the specified class period are encouraged to stay informed about the ongoing legal developments. Engaging with The Gross Law Firm can provide shareholders with the...

Continue Reading
Zymeworks Stock Target Steady After Positive Trial Results

Updated Category News Views 89

Zymeworks Keeps Stock Rating Steady After ESMO 2024 Results Zymeworks Inc. (NASDAQ: ZYME) has maintained its stock rating and price target after revealing encouraging results from its recent cancer treatment clinical trials at a significant medical conference. The ratings firm H.C. Wainwright has reiterated a Neutral rating and set a price target of $10.00 per share...

Continue Reading
Exploring New Opportunities in Convertible Bonds with BMAX ETF

Updated Category News Views 253

Introduction to the New ETF A recently introduced exchange-traded fund (ETF), known as the REX Bitcoin Corporate Treasury Convertible Bond ETF (BMAX), is gaining attention for its focus on convertible bonds from companies that have Bitcoin included in their financial strategies. This ETF began trading recently and represents a growing trend in the investment landscape....

Continue Reading
iBio Secures Strategic Investments to Propel Biotech Advancements

Updated Category News Views 140

iBio's Strategic Investment Announcement iBio, Inc. (NYSE: IBIO), a pioneer in AI-driven antibody immunotherapies, has made an impactful stride in its mission, announcing the successful closure of a private investment offering totaling over $650,000 from its Board of Directors and corporate officers. This investment is a significant vote of confidence in iBio's strategy...

Continue Reading
Simulmedia Welcomes Jonathan Steuer as Chief Scientist

Updated Category News Views 111

Simulmedia Appoints Jonathan Steuer as Chief Scientist Simulmedia, a leader in cross-channel TV and connected TV (CTV) advertising, is thrilled to announce a significant addition to its executive team. Jonathan Steuer, a prominent figure in media research and data science, has been appointed as the Chief Scientist. With a remarkable background as a scientist and...

Continue Reading